JAGX - ジャガ―・アニマル・ヘルス (Jaguar Health Inc.) ジャガ―・アニマル・ヘルス

 JAGXのチャート


 JAGXの企業情報

symbol JAGx
会社名 Jaguar Animal Health Inc (ジャガ―・アニマル・ヘルス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジャガー・ヘルス(Jaguar Health Inc.)(旧名:Jaguar Animal Health Inc.)は天然製品医薬品会社である。同社は人の処方箋使用及び動物のためのグローバルで、新規で持続可能な派生の消化器製品の開発及び製品化に従事する。Napo Pharmaceuticals Inc.を通じて、伝統的に熱帯雨林地域で使用される植物から、世界市場向けに独自のヒト胃腸薬を開発・商品化することを行う。Mytesiは、抗レトロウィルス療法に対するヒト免疫不全ウイルスHIV /後天性免疫不全症候群(AIDS)を有する成人患者における非感染性下痢の症候性軽減のために示される抗下痢剤である。他の製品はCanalevia、Equilevia、Neonorm Calf及びNeonorm Foalを含む。   ジャガ―・アニマル・ヘルスは米国の動物用医薬品メ―カ―。ペットや生産動物用の胃腸用治療薬の開発や商品化に焦点を当てる。主な薬品候補には、犬用の水溶性下痢治療処方薬「Canalevia」がある。また、非処方箋薬として、離乳前の酪農子牛用の水溶性下痢治療薬「Neonorm」を開発。本社はサンフランシスコ。   Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Its Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
本社所在地 201 Mission Street Suite 2375 San Francisco CA 94105 USA
代表者氏名 James J. Bochnowski ジェームズJ.ボノフノキ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 415-896-5081
設立年月日 41426
市場名 NASDAQ Small Cap
ipoyear 2015年
従業員数
url https://jaguar.health/
nasdaq_url https://www.nasdaq.com/symbol/jagx
adr_tso
EBITDA EBITDA(百万ドル) -19.94703
終値(lastsale) 0.5701
時価総額(marketcap) 28407706.734
時価総額 時価総額(百万ドル) 14.40071
売上高 売上高(百万ドル) 4.33046
企業価値(EV) 企業価値(EV)(百万ドル) 36.40752
当期純利益 当期純利益(百万ドル) -29.79644
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Jaguar Health Inc revenues decreased 2% to $1.7M. Net loss applicable to common stockholders increased from $6.5M to $14.3M. Revenues reflect Collaboration revenue decrease of 89% to $177K. Higher net loss reflects Sales and marketing expense increase from $280K to $4.4M (expense) Interest expense increase from $336K to $1.3M (expense) General and administrative expense increase of 11% to $6.1M (expense).

 JAGXのテクニカル分析


 JAGXのニュース

   Jaguar Health''s Italian firm applies for orphan drug designation for crofelemer to EMA  2022/05/25 13:26:56 Seeking Alpha
Jaguar Health (JAGX) said on Wednesday its Italian firm Napo Therapeutics had submitted an Orphan Drug Designation application for crofelemer to treat a rare congenital diarrhea…
   Jaguar Health Announces Launch of the First U.S. Canine Cancer Registry and Canine Cancer Care Index  2022/05/23 11:00:00 Jaguar Health
"Canine Cancer: Take C.H.A.R.G.E." (Canine Health And ReGistry Exchange) Based on Nationwide Gallup Poll of Pet Owners and Initial Assessment of More Than 35,000 Canine Medical Records Initial Data from Gallup Poll of More Than 3,500 Dog Owners Suggest Nearly Five-Fold Greater Incidence of Canine
   Jaguar Health GAAP EPS of -$0.40 misses by $0.23, revenue of $2.62M beats by $1M  2022/05/10 12:03:47 Seeking Alpha
Jaguar Health press release (JAGX): Q1 GAAP EPS of -$0.40 misses by $0.23.Non-GAAP EBITDA for the first quarter of 2022 and the first quarter of 2021 was a net loss of $9.4 million…
   Jaguar Health Q1 2022 Earnings Preview  2022/05/09 16:45:59 Seeking Alpha
Jaguar Health (JAGX) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open.The consensus EPS Estimate is -$0.18 (-80.0% Y/Y) and the consensus…
   Jaguar Health Inc. (NASDAQ: JAGX) Slid -5.45% In 6 Months Getting Ready For What’s Next  2022/05/07 20:00:00 Marketing Sentinel
Jaguar Health Inc. (NASDAQ:JAGX)’s traded shares stood at 0.7 million during the last session, with the company’s beta value hitting 1.82. At the close of trading, the stock’s price was $0.42, to imply a decrease of -5.28% or -$0.03 in intraday trading. The JAGX share’s 52-week high remains $6.84, putting it -1528.57% down since that … Jaguar Health Inc. (NASDAQ: JAGX) Slid -5.45% In 6 Months Getting Ready For What’s Next Read More »
   Jaguar Health Q1 2022 Earnings Preview  2022/05/09 16:45:59 Seeking Alpha
Jaguar Health (JAGX) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open.The consensus EPS Estimate is -$0.18 (-80.0% Y/Y) and the consensus…
   Jaguar Health Inc. (NASDAQ: JAGX) Slid -5.45% In 6 Months Getting Ready For What’s Next  2022/05/07 20:00:00 Marketing Sentinel
Jaguar Health Inc. (NASDAQ:JAGX)’s traded shares stood at 0.7 million during the last session, with the company’s beta value hitting 1.82. At the close of trading, the stock’s price was $0.42, to imply a decrease of -5.28% or -$0.03 in intraday trading. The JAGX share’s 52-week high remains $6.84, putting it -1528.57% down since that … Jaguar Health Inc. (NASDAQ: JAGX) Slid -5.45% In 6 Months Getting Ready For What’s Next Read More »
   Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)  2022/05/06 20:15:00 Wallstreet:Online
SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective May 6, 2022, the Company granted 50,000 restricted stock units (RSUs) to Mark Johnson, a new employee hired …
   Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs  2022/05/03 12:30:00 Wallstreet:Online
Canalevia® Would Be the First and Only Treatment for EID in Dogs To Receive Any Type of Approval From FDASAN FRANCISCO, CA / ACCESSWIRE / May 3, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary …
   Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs  2022/04/27 14:20:00 Wallstreet:Online
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDASAN FRANCISCO, CA / ACCESSWIRE / April 27, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary …
   Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs  2022/05/03 12:30:00 Wallstreet:Online
Canalevia® Would Be the First and Only Treatment for EID in Dogs To Receive Any Type of Approval From FDASAN FRANCISCO, CA / ACCESSWIRE / May 3, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary …
   Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs  2022/04/27 14:20:00 Wallstreet:Online
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDASAN FRANCISCO, CA / ACCESSWIRE / April 27, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary …
   Jaguar Health Inc. (NASDAQ: JAGX) Continues To Be Hot This Week?  2022/04/26 12:30:00 Stocks Register
Jaguar Health Inc. (NASDAQ:JAGX) traded at $0.48 at close of the session on Monday, 04/25/22, made a downward move of -3.44% on its previous day’s price. Looking at the stock we see that its previous close was $0.50 and the beta (5Y monthly) reads 1.48 with the day’s price range being $0.466 – $0.5024. In … Jaguar Health Inc. (NASDAQ: JAGX) Continues To Be Hot This Week? Read More »
   Jaguar Health Inc. (NASDAQ: JAGX) Shares Are Set To Rise By 2022  2022/04/22 15:30:00 Stocks Register
Jaguar Health Inc. (NASDAQ:JAGX) shares, rose in value on Thursday, April 21, with the stock price down by -7.60% to the previous day’s close as strong demand from buyers drove the stock to $0.50. Actively observing the price movement in the last trading, the stock closed the session at $0.54, falling within a range of … Jaguar Health Inc. (NASDAQ: JAGX) Shares Are Set To Rise By 2022 Read More »
   Staggering stocks: Jaguar Health, Inc. (NASDAQ:JAGX -3.97%), Uranium Energy Corp. (AMEX:UEC -2.14%)  2022/04/18 13:59:18 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Staggering stocks: Jaguar Health, Inc. (NASDAQ:JAGX -3.97%), Uranium Energy Corp. (AMEX:UEC -2.14%) appeared first on Stocks Equity .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジャガ―・アニマル・ヘルス JAGX Jaguar Health Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)